Analysis

Drugmakers Fight Multifront Legal Battles Over GLP-1s

By Hannah Albarazi · January 6, 2026, 5:58 PM EST

In the years since the U.S. Food and Drug Administration approved GLP-1 drugs for Type 2 diabetes and, later, for weight loss, demand has surged, generating estimated revenues of more than...

To view the full article, register now.

Case Information

Case Title

Novo Nordisk Inc. et al v. Mylan Pharmaceuticals Inc.

Case Number

1:23-cv-00101

Court

Delaware

Nature of Suit

Patent - Abbreviated New Drug Application(ANDA)

Date Filed

January 27, 2023


Case Title

Novo Nordisk Inc. et al v. Sun Pharmaceutical Industries Ltd. et al

Case Number

1:23-cv-01459

Court

Delaware

Nature of Suit

Patent - Abbreviated New Drug Application(ANDA)

Date Filed

December 21, 2023


Case Title

GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) PRODUCTS LIABILITY LITIGATION

Case Number

2:24-md-03094

Court

Pennsylvania Eastern

Nature of Suit

P.I.: Health Care/Pharmaceutical Personal Injury Product Liability

Date Filed

February 05, 2024


Case Title

Novo Nordisk A/S et al v. Ambose Medical, LLC

Case Number

1:24-cv-11541

Court

Illinois Northern

Nature of Suit

840 Trademark

Date Filed

November 08, 2024


Case Title

Jones v. Dudum et al

Case Number

3:25-cv-05866

Court

California Northern

Nature of Suit

Stockholders Suits

Date Filed

July 14, 2025


Case Title

BARTA v. NOVO NORDISK A/S et al

Case Number

3:25-cv-14045

Court

New Jersey

Nature of Suit

Securities/Commodities

Date Filed

August 01, 2025